Emmecell Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for EO2002 for the Treatment of Corneal Endothelial Disease

Emmecell received FDA RMAT designation for its EO2002 regenerative cell therapy for corneal endothelial disease, advancing the clinical/regulatory pathway. The RMAT status is a meaningful positive regulatory milestone that can accelerate development and potentially de-risk timelines for the program.

Analysis

Emmecell received FDA RMAT designation for its EO2002 regenerative cell therapy for corneal endothelial disease, advancing the clinical/regulatory pathway. The RMAT status is a meaningful positive regulatory milestone that can accelerate development and potentially de-risk timelines for the program.